Cargando…

Association of serum lipid levels and clinical outcomes in early breast cancer patients

BACKGROUND: The association between dyslipidaemia and breast cancer remains controversial, especially regarding the dynamic changes in lipid levels. OBJECTIVES: This study aimed to elucidate the role of serum lipid levels and the changes in disease outcomes in patients with breast cancer. METHODS: T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Shuwen, Yu, Jing, Chen, Xiaosong, Shen, Kunwei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10226318/ https://www.ncbi.nlm.nih.gov/pubmed/37256022 http://dx.doi.org/10.1177/17588359231177004

Ejemplares similares

Metabolic Syndrome and Breast Cancer: Prevalence, Treatment Response, and Prognosis
por: Dong, Shuwen, et al.
Publicado: (2021)

Association of Ki-67 Change Pattern After Core Needle Biopsy and Prognosis in HR+/HER2− Early Breast Cancer Patients
por: Li, Shuai, et al.
Publicado: (2022)

Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients
por: Lu, Yujie, et al.
Publicado: (2021)

A Smartphone-Based App to Improve Adjuvant Treatment Adherence to Multidisciplinary Decisions in Patients With Early-Stage Breast Cancer: Observational Study
por: Yu, Jing, et al.
Publicado: (2021)

Compliance with multidisciplinary team recommendations and disease outcomes in early breast cancer patients: An analysis of 4501 consecutive patients
por: Yang, Xingxia, et al.
Publicado: (2020)

Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes
por: Wang, Haoyu, et al.
Publicado: (2020)

Time interval between breast cancer diagnosis and surgery is associated with disease outcome
por: Zhu, Siji, et al.
Publicado: (2023)

Association of molecular subtype concordance and survival outcome in synchronous and metachronous bilateral breast cancer
por: Ding, Shuning, et al.
Publicado: (2021)

21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients
por: Zhu, Yifei, et al.
Publicado: (2021)

Weight Gain during Neoadjuvant Chemotherapy is Associated with Worse Outcome among the Patients with Operable Breast Cancer
por: Fang, Qiong, et al.
Publicado: (2019)

Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients
por: Cai, Lifen, et al.
Publicado: (2020)

Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer
por: Lian, Bi, et al.
Publicado: (2023)

Accuracy of ultrasonographic changes during neoadjuvant chemotherapy to predict axillary lymph node response in clinical node-positive breast cancer patients
por: Li, Zhuoxuan, et al.
Publicado: (2022)

Association of Molecular Biomarker Heterogeneity With Treatment Pattern and Disease Outcomes in Multifocal or Multicentric Breast Cancer
por: Li, Shuai, et al.
Publicado: (2022)

A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer
por: Wang, Zheng, et al.
Publicado: (2020)

Can HER2 1+ Breast Cancer Be Considered as HER2-Low Tumor? A Comparison of Clinicopathological Features, Quantitative HER2 mRNA Levels, and Prognosis among HER2-Negative Breast Cancer
por: Shu, Lan, et al.
Publicado: (2022)

Single‐cell RNA sequencing in breast cancer: Understanding tumor heterogeneity and paving roads to individualized therapy
por: Ding, Shuning, et al.
Publicado: (2020)

Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2- early breast cancer
por: Gao, Weiqi, et al.
Publicado: (2019)

Sonography with vertical orientation feature predicts worse disease outcome in triple negative breast cancer
por: Wang, Haoyu, et al.
Publicado: (2019)

Association of tumor immune microenvironment profiling and 21-gene recurrence assay in early breast cancer patients
por: Tong, Yiwei, et al.
Publicado: (2022)

Identification of Ten Mitosis Genes Associated with Tamoxifen Resistance in Breast Cancer
por: Sun, Xi, et al.
Publicado: (2021)

Ki67 increase after core needle biopsy associated with worse disease outcome in HER2-negative breast cancer patients
por: Tong, Yiwei, et al.
Publicado: (2023)

Long Noncoding RNA Signature and Disease Outcome in Estrogen Receptor-Positive Breast Cancer Patients Treated with Tamoxifen
por: Wang, Gen, et al.
Publicado: (2018)

Association of Obesity and Luminal Subtypes in Prognosis and Adjuvant Endocrine Treatment Effectiveness Prediction in Chinese Breast Cancer Patients
por: Tong, Yiwei, et al.
Publicado: (2022)

Pathological underestimation and biomarkers concordance rates in breast cancer patients diagnosed with ductal carcinoma in situ at preoperative biopsy
por: Zhou, Hemei, et al.
Publicado: (2022)

Association of tumor‐infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer
por: Hong, Jin, et al.
Publicado: (2021)

Association between tumor molecular subtype, clinical stage and axillary pathological response in breast cancer patients undergoing complete pathological remission after neoadjuvant chemotherapy: potential implications for de-escalation of axillary surgery
por: Hong, Jin, et al.
Publicado: (2021)

Decision-making of Adjuvant Chemotherapy for Breast Cancer Patients with Discordant Risk Classifications between Clinical-Pathological Factors and 21-gene Recurrence Score
por: Gao, Weiqi, et al.
Publicado: (2020)

Prognostic Factors and Surgery for Breast Cancer Patients With Locoregional Recurrence: An Analysis of 5,202 Consecutive Patients
por: Huang, Jiahui, et al.
Publicado: (2021)

Non-anthracycline-containing docetaxel and cyclophosphamide regimen is associated with sustained worse outcome compared with docetaxel, anthracycline and cyclophosphamide in neoadjuvant treatment of triple negative and HER2-positive breast cancer patients: updated follow-up data from NATT study
por: Chen, Xiaosong, et al.
Publicado: (2016)

Cancer-Associated Adipocytes and Breast Cancer: Intertwining in the Tumor Microenvironment and Challenges for Cancer Therapy
por: Wu, Chenghui, et al.
Publicado: (2023)

Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26–30
por: Yu, Jing, et al.
Publicado: (2020)

Distribution, dynamic evolution, and clinical outcomes of patients with advanced breast cancer according to HER2 expression
por: Shi, Qin, et al.
Publicado: (2023)

CRISPR-cas9 Screening Identified Lethal Genes Enriched in Cell Cycle Pathway and of Prognosis Significance in Breast Cancer
por: Sun, Xi, et al.
Publicado: (2021)

Clinical characteristics, tumor‐infiltrating lymphocytes, and prognosis in HER2‐low breast cancer: A comparison study with HER2‐zero and HER2‐positive disease
por: Lu, Yujie, et al.
Publicado: (2023)

HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab
por: Li, Shuai, et al.
Publicado: (2020)

Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients
por: Li, Shuai, et al.
Publicado: (2021)

Association between insulin resistance and cardiac remodeling in HER2-positive breast cancer patients: a real-world study
por: Shi, Yunjing, et al.
Publicado: (2023)

Associations of clinicopathological factors with local treatment and survival outcome in elderly patients with ductal carcinoma in situ
por: Zhang, Xu, et al.
Publicado: (2023)

The association between serum lipid levels and histological type of breast cancer
por: Wang, Xinru, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_loj1d2pt78dfjl9n4oo6b5d3hm